Keyphrases
High Dose
100%
Bone Turnover Markers
100%
Prospective Follow-up
100%
Asthmatic
100%
Ciclesonide
100%
Airway Hyperresponsiveness
80%
Type I Collagen
60%
PIIINP
60%
Amino
40%
Urinary Cortisol
40%
Adrenal Suppression
40%
Systemic Side Effects
40%
Bronchial Challenge
40%
Asthma Symptoms
40%
Bone Turnover
40%
Mannitol
40%
Creatinine Ratio
40%
Propeptide
40%
Scotland
20%
Primary Care
20%
No Significant Difference
20%
Tayside
20%
Group-based
20%
Cross-linked
20%
Carboxyl Terminus
20%
Persistent Asthma
20%
Pulmonary Function
20%
Prospective Randomized Trial
20%
Inhaled Corticosteroid Therapy
20%
Parallel Trials
20%
Reliever Use
20%
Resorption
20%
Bone Metabolism
20%
Type III Collagen
20%
C-telopeptide
20%
Telopeptide
20%
Stored Samples
20%
Use Function
20%
Airway Control
20%
Sensitive Biomarker
20%
Medicine and Dentistry
Drug Megadose
100%
Low Drug Dose
100%
Bone Turnover
100%
Ciclesonide
100%
Respiratory Tract Allergy
80%
Asthma
60%
Collagen Type 1
60%
Amino Terminal Sequence
40%
Adrenal Suppression
40%
Urinary System
40%
Adverse Event
40%
Hydrocortisone
40%
Creatinine
40%
Telopeptide
40%
Mannitol
40%
Primary Health Care
20%
Lung Function
20%
Group Trial
20%
Biological Marker
20%
Salicylate Sodium
20%
Corticosteroid Therapy
20%
Ossification
20%
Post-Hoc Analysis
20%
Airway Management
20%
Collagen Type 3
20%
Bone Remodeling
20%
Pharmacology, Toxicology and Pharmaceutical Science
Ciclesonide
100%
Respiratory Tract Allergy
80%
Asthma
60%
Collagen Type 1
60%
Adverse Event
40%
Hydrocortisone
40%
Creatinine
40%
Mannitol
40%
Telopeptide
40%
Biological Marker
20%
Group Trial
20%
Salicylate Sodium
20%
Collagen Type 3
20%